1Ciardiello F,Tortom G.EGFR antagonists in cancer treatment[J].N Engl J Med,2008,358(11):1160-1174.
2Hilger RA,Scheulen ME,Strumberg D.The Ras-Raf-MEK-ERK pathway in the treatment of cancer[J].Onkologie,2002,25(6):511-518.
3Fresno Vara JA,Casado E,de Castro J,et al.P13K/Akt signalling pathway and cancer[J].Cancer Treat Rev,2004,30(2):193-204.
4Akimoto T,Hunter NR,Buchmiilar L,et al.Inverse relationship between epidermal growth factor receptor expression and radiecurability of murine carcinomas[J].Clin Cancer Res,1999,5(1O):2884-2890.
5Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous eell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
6Posner MR,wirth LJ.Cetuximab and radiotherapy for head and neck cancer[J].N Engl J Med,2006,354(6):634-636.
7Vermorken JB,Mesia R,Rivera F,et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J].N Engl J Med,2008,359(11):1116-1127.
8Burtness B,Goldwasser MA,Flood W,et al.Phase Ⅲ randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer:an Eastern Cooperative Oncology Group Study[J].J Clin Oncol,2005,23(34):8646-8654.
9Cohen EE,Rosen F,Stadler WM,et al.Phase Ⅱ trial of ZD1839 in recurrent or metastatic 8qnamoug cell carcinoma of the head and neck[J].J Clin Oncol,2003,21(10):1980-1987.
10Cohen EE,Kane MA,List MA,et al.Phase Ⅱ trial of gefitinib 250 rag daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J].Clin Cancer Res,2005,11(23):8418-8424.
同被引文献13
1Liu J, Shao C, Tan ML, et al. Molecular biology of adenoid cystic carcinoma [J]. Head Neck, 2012, 34(11): 1665-1677.
2Liu AM, Wong KF, Jiang X, et al. Regulators of mammalian Hippo pathway in cancer[J]. Biochim Biophys Acta, 2012, 1826(2):357-364.
3Fan R, Kim NG, Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-l[J]. Proc Natl Acad Sci U S A, 2013, 110(7):2569-2574.
4Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway [J]. Biochim Biophys Acta, 2013, 1830(2):2323- 2334.
5Barry ER, Camargo FD. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development [J]. Curr Opin Cell Biol, 2013, 25(2):247-253.
6Yuan S, Yu SL, Chen HY, et ah Clustered genomic alterations in chromosome 7P dictate outcomes and targeted treatment responses of lung adenolarcinoma with EGFR-activating mutations [J]. J Clin Oncol, 201129(25): 3435-3442.
7Antonieelli A, Cafarotti S, Indini A, et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation [J]. Int J Med Sci, 2013, 10(3):320- 330.
